

Anna Diana

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7722744/publications.pdf>

Version: 2024-02-01

24
papers

727
citations

686830

13
h-index

713013

21
g-index

24
all docs

24
docs citations

24
times ranked

1582
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis. <i>Frontiers in Oncology</i> , 2022, 12, 813462.	1.3	2
2	Cancer Treatment-Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy. <i>Current Treatment Options in Oncology</i> , 2021, 22, 45.	1.3	20
3	Bone Metastases from Gastric Cancer: What We Know and How to Deal with Them. <i>Journal of Clinical Medicine</i> , 2021, 10, 1777.	1.0	8
4	Epigenetic Regulation in Melanoma: Facts and Hopes. <i>Cells</i> , 2021, 10, 2048.	1.8	20
5	Gestational choriocarcinoma with residual lung tumor after completing treatment: a case report. <i>International Journal of Surgery Oncology</i> , 2021, 5, 107.	0.2	1
6	Primary acinic cell carcinoma of the breast is associated with a poor outcome: A case report and literature review. <i>Molecular and Clinical Oncology</i> , 2021, 16, 43.	0.4	8
7	PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?. <i>Frontiers in Oncology</i> , 2020, 10, 782.	1.3	11
8	Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes. <i>Cancers</i> , 2020, 12, 819.	1.7	61
9	Lobular Breast Cancer: A Review. <i>Frontiers in Oncology</i> , 2020, 10, 591399.	1.3	46
10	Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response. <i>Frontiers in Oncology</i> , 2019, 9, 1289.	1.3	10
11	PARP inhibitors in ovarian cancer. <i>Cancer Treatment Reviews</i> , 2019, 73, 1-9.	3.4	158
12	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 474-485.	5.1	59
13	Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy). <i>Journal of Breast Oncology</i> , 2018, 11, 1-7.	0.784314	14
14	Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score Analysis. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-7.	0.7	21
15	Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs. <i>Current Oncology Reports</i> , 2018, 20, 76.	1.8	72
16	Three dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs. <i>Breast</i> , 2018, 41, 165-171.	0.9	12
17	Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial). <i>ESMO Open</i> , 2017, 2, e000176.	2.0	10
18	Phosphatidylinositol 3-kinase (PI3K)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells. <i>Oncotarget</i> , 2017, 8, 76479-76491.	0.8	24

#	ARTICLE	IF	CITATIONS
19	Comparison of the current AJCC-TNM numeric-based with a new anatomical location-based lymph node staging system for gastric cancer: A western experience. PLoS ONE, 2017, 12, e0173619.	1.1	16
20	NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice. BMC Cancer, 2016, 16, 709.	1.1	48
21	Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: a propensity score-matched analysis. ESMO Open, 2016, 1, e000038.	2.0	66
22	Pancreatic neuroendocrine tumors: Nosography, management and treatment. International Journal of Surgery, 2016, 28, S156-S162.	1.1	42
23	Final results of neutrophil-to-lymphocyte ratio (NLR) as a prognostic marker in advanced pancreatic cancer patients treated with Nab-paclitaxel plus Gemcitabine.. Journal of Clinical Oncology, 2016, 34, e15737-e15737.	0.8	0
24	Baseline neutrophil-lymphocyte ratio as a prognostic factor for patients with resectable gastric cancer undergoing adjuvant chemotherapy.. Journal of Clinical Oncology, 2015, 33, e15018-e15018.	0.8	0